As a phase II antioxidant enzyme, NQO1, being regulated by NRF2, is aberrantly upregulated in multiple cancers such as pancreatic cancer52, glioblastoma53, lung cancer54, and breast cancer55, and contributes a lot to therapy resistance, especially for radioresistance. Here, NQO1 is linked to cancer.